Levodopa Pharmacokinetics in Brain after Both Oral and Intravenous Levodopa in One Patient with Advanced Parkinson's Disease
PDF) Continuous levodopa for advanced Parkinson's disease
Studies of the Rate Constant of Levodopa Methyl Ester Hydrolysis by LC
Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease | Journal of Pharmacology and Experimental Therapeutics
Frontiers | Mathematical Insights into the Effects of Levodopa
PDF) Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson's Disease
Frontiers | Histological Correlates of Neuroanatomical Changes in a Rat Model of Levodopa-Induced Dyskinesia Based on Voxel-Based Morphometry
Concomitant short‐ and long‐duration response to levodopa in the 6‐OHDA‐lesioned rat: a behavioural and molecular study - Marin - 2007 - European Journal of Neuroscience - Wiley Online Library
Levodopa Pharmacokinetics in Brain after Both Oral and Intravenous Levodopa in One Patient with Advanced Parkinson's Disease
PDF) Profile of levodopa/carbidopa intestinal gel and its potential in the treatment of advanced Parkinson's disease
Frontiers | Histological Correlates of Neuroanatomical Changes in a Rat Model of Levodopa-Induced Dyskinesia Based on Voxel-Based Morphometry
Lowered cAMP and cGMP signalling in the brain during levodopa‐induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms - Giorgi - 2008 - European Journal of Neuroscience - Wiley Online Library
Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia
l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? - Carta - 2017 - European Journal of Neuroscience - Wiley Online Library
Levodopa Pharmacokinetics in Brain after Both Oral and Intravenous Levodopa in One Patient with Advanced Parkinson's Disease
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap - The Lancet Neurology
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap - The Lancet Neurology
Evaluation of Levodopa Dose and Magnitude of Dopamine Depletion as Risk Factors for Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease | Journal of Pharmacology and Experimental Therapeutics
Brain Sciences | Free Full-Text | Transcriptome Sequencing Reveal That Rno-Rsf1_0012 Participates in Levodopa-Induced Dyskinesia in Parkinson’s Disease Rats via Binding to Rno-mir-298-5p | HTML
Lowered cAMP and cGMP signalling in the brain during levodopa‐induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms - Giorgi - 2008 - European Journal of Neuroscience - Wiley Online Library
Frontiers | Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence
Frontiers | The Human Experience with Intravenous Levodopa
Levodopa-Induced Dyskinesia in Parkinson's Disease
Impairment of neuronal mitochondrial function by l-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage | Cell Death Discovery
